Nuwellis Appoints Carisa Schultz as Chief Financial Officer
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz joins from NeueHealth, where she served as Vice President of Finance and led enterprise finance, treasury, and corporate development.
Her background includes roles at Boston Scientific and Big Four public accounting, bringing public-company healthcare and medical-technology finance experience to support Nuwellis’ next phase of growth.
Positive
- Appointing a CFO with public-company healthcare finance experience
- Start date set for February 2, 2026 enabling immediate leadership continuity
- Proven experience leading enterprise finance, treasury, and corporate development
Negative
- None.
Details
News Market Reaction – NUWE
On Jan 30, the day this news came out, NUWE closed 10.02% below the previous close.
Data tracked by StockTitan Argus for the Jan 30 session.
Key Figures
- Q3 2025 net sales
- $2.217M
- Quarter ended September 30, 2025 (vs. $2.367M prior year)
- Q3 2025 gross margin
- 65.2%
- Quarter ended September 30, 2025 (vs. 70.0% prior year)
- Q3 2025 net income
- $468,000
- Aided by $3.161M non-cash gain on warrant liabilities
- YTD 2025 net loss
- $15.099M
- Year-to-date through September 30, 2025
- Operating cash outflow
- $7.780M
- Operating cash flow for nine months ended September 30, 2025
- Cash balance
- $3.094M
- Cash and equivalents as of September 30, 2025; going concern doubt noted
- ATM capacity
- $4,650,000
- Common stock at-the-market program with Ladenburg Thalmann
- NIH grant
- $3 million
- Multi-year grant to partner KBT supporting Vivian pediatric CRRT
Historical Context
-
$5M private placement and warrant inducement priced at-the-market.
-
Agreement to acquire Rendiatech to expand real-time kidney monitoring.
-
Resignations and appointments reshaping board with added governance expertise.
-
New U.S. patent for pediatric extracorporeal therapy safety mechanisms.
-
Lenox Hill study data supporting Aquadex use across critical-care settings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cardiorenal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growth
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026.
Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including Associate Vice President, Enterprise Finance and Director, Finance.
Ms. Schultz brings deep healthcare and medical technology finance experience, including early career experience at Boston Scientific, alongside leadership roles across public and private healthcare organizations. Her background also includes Big Four public accounting and senior financial analysis leadership roles supporting growth, operational discipline, and strategic decision-making.
“Carisa is a highly accomplished financial leader with strong public-company experience and a deep understanding of healthcare and medical technology,” said John Erb, Chief Executive Officer of Nuwellis. “Her expertise and disciplined approach will be instrumental as we continue to execute our strategy and advance our cardiorenal platform.”
“I’m excited to join Nuwellis at an important juncture in its growth,” said Ms. Schultz. “The company’s focus on precision cardiorenal care represents a meaningful opportunity, and I look forward to working with the leadership team to support long-term value creation.”
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company advancing precision fluid management technologies across the cardiorenal continuum. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.